Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 22, 2024 11:27 ET | Source: ProLynx Inc.

ProLynx 宣布其长效药物司美格鲁肽的临床前研究结果，表明该药物仅需每月使用一次

旧金山, Aug. 22, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. 今日宣布其利用自主技术成功研发出一款长效药物司美格鲁肽。该药物可以每月使用一次。ProLynx 技术的创新之处在于，借助具有可调节预设释放速率的连接肽，将治疗药物与水凝胶微球精确结合。司美格鲁肽是一种肽类 GLP-1 激动剂，这是 Novo Nordisk 畅销药物 Ozempic® 和...
August 22, 2024 11:27 ET | Source: ProLynx Inc.

ProLynx gibt präklinische Ergebnisse zu langwirksamem Semaglutid mit einmal monatlicher Dosierung bekannt

SAN FRANCISCO, Aug. 22, 2024 (GLOBE NEWSWIRE) -- Das Unternehmen ProLynx Inc. hat heute bekannt gegeben, dass mithilfe seiner Technologie ein langwirksames Semaglutid hergestellt worden ist, das...
August 22, 2024 11:27 ET | Source: ProLynx Inc.

ProLynx annonce des résultats précliniques pour le sémaglutide à action prolongée nécessitant une administration mensuelle

SAN FRANCISCO, 22 août 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. a annoncé aujourd'hui que sa technologie avait permis de créer un sémaglutide à action prolongée pouvant être administré une fois...
August 21, 2024 14:16 ET | Source: ProLynx Inc.

ProLynx announces preclinical results of long-acting semaglutide requiring once monthly dosing

SAN FRANCISCO, Aug. 21, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced the use of their technology to create a long-acting semaglutide that can be administered once monthly. The ProLynx...
March 25, 2024 09:00 ET | Source: ProLynx Inc.

ProLynx announces initiation of the Phase II Topology clinical trial of its DNA-damaging agent PLX038 in triple-negative breast cancer at the Institut Curie

SAN FRANCISCO, March 25, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced that the first patient was included in TOPOLOGY by investigator Dr. Delphine Loirat, with a Phase II clinical trial...
February 05, 2024 09:00 ET | Source: ProLynx Inc.

ProLynx announces initiation of Phase I/II clinical trial of its DNA-damaging agent PLX038 in patients with rare CNS tumors at the National Cancer Institute (NCI)

SAN FRANCISCO, Feb. 05, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc. announced today that the first patient was treated with PLX038 (PEGylated SN-38) in a Phase I/II clinical trial for primary CNS tumors...
January 24, 2024 09:00 ET | Source: ProLynx LLC

ProLynx announces a publication proposing that a long-acting prodrug of SN-38 could be effective in treating Sacituzumab Govitecan-Resistant Tumors

SAN FRANCISCO, Jan. 24, 2024 (GLOBE NEWSWIRE) -- ProLynx Inc., a biotech company with a unique technology for tunable half-life extension of drugs, announced publication of a paper entitled “Could...
October 07, 2022 13:57 ET | Source: ProLynx LLC

ProLynx kündigt den Beginn einer klinischen Phase-II-Studie mit dem DNA-schädigenden Wirkstoff PLX038 bei Patientinnen mit platinresistentem Eierstockkrebs an der Mayo Clinic an

SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. gab heute bekannt, dass die erste Patientin in einer klinischen Phase-II-Studie zu platinresistentem Eierstockkrebs an der Mayo Clinic...
October 07, 2022 13:57 ET | Source: ProLynx LLC

ProLynx annonce le lancement d'un essai clinique de phase II sur son agent endommageant l'ADN, PLX038, chez des patientes atteintes d'un cancer de l'ovaire résistant au platine à la Mayo Clinic

SAN FRANCISCO, 07 oct. 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. a annoncé aujourd'hui que la première patiente a reçu le PLX038 (PEG~SN-38) dans le cadre d'un essai clinique de phase II sur le cancer...
October 07, 2022 09:00 ET | Source: ProLynx LLC

ProLynx announces initiation of Phase II clinical trial of its DNA-damaging agent PLX038 in patients with platinum-resistant Ovarian Cancer at the Mayo Clinic

SAN FRANCISCO, Oct. 07, 2022 (GLOBE NEWSWIRE) -- ProLynx Inc. today announced that the first patient was treated with PLX038 (PEG~SN-38) in a Phase II clinical trial for platinum-resistant ovarian...

Next Page keyboard_arrow_right